Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. monthly Stock Chart
Biogen Inc.
IndexS&P 500 P/E9.85 EPS (ttm)28.24 Insider Own0.63% Shs Outstand184.82M Perf Week-2.80%
Market Cap51.41B Forward P/E8.48 EPS next Y32.80 Insider Trans-0.09% Shs Float175.30M Perf Month-7.77%
Income5.42B PEG1.42 EPS next Q7.89 Inst Own92.00% Short Float2.47% Perf Quarter-0.24%
Sales14.23B P/S3.61 EPS this Y24.50% Inst Trans-0.05% Short Ratio2.48 Perf Half Y16.76%
Book/sh76.06 P/B3.66 EPS next Y-0.71% ROA20.50% Target Price304.29 Perf Year-16.44%
Cash/sh24.01 P/C11.58 EPS next 5Y6.93% ROE40.10% 52W Range215.77 - 338.87 Perf YTD-6.26%
Dividend- P/FCF7.78 EPS past 5Y22.70% ROI23.60% 52W High-17.92% Beta1.19
Dividend %- Quick Ratio1.70 Sales past 5Y14.20% Gross Margin86.00% 52W Low28.90% ATR5.98
Employees7800 Current Ratio1.90 Sales Q/Q4.70% Oper. Margin47.10% RSI (14)32.07 Volatility1.84% 1.96%
OptionableYes Debt/Eq0.43 EPS Q/Q17.30% Profit Margin37.90% Rel Volume0.72 Prev Close284.21
ShortableYes LT Debt/Eq0.32 EarningsJan 28 BMO Payout0.00% Avg Volume1.75M Price278.14
Recom2.70 SMA20-5.16% SMA50-5.29% SMA20010.90% Volume1,258,450 Change-2.14%
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Jan-23-20 09:21AM  The one value strategy that wasnt a disaster now favors commodity sector over techs MarketWatch
08:51AM  Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks
01:18AM  Roche's risdiplam meets primary endpoint in trial of SMA drug in infants Reuters
Jan-21-20 06:21PM  Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks
02:50PM  Mass. employers earn high marks in LGBTQ-friendly workplace index American City Business Journals
Jan-20-20 05:32PM  Top Long-Term Growth Stocks in the Health Care Sector
Jan-16-20 01:10PM  FDA Risks Sacrificing Its Standards for Speed Bloomberg
05:00AM  Top Picks 2020- Ionis Pharmaceuticals IONS MoneyShow
Jan-15-20 05:50PM  4 High-Quality Health Care Companies for 2020
05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-14-20 01:02PM  Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc. Moody's
09:55AM  Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M Zacks
Jan-13-20 08:46AM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB Benzinga
07:51AM  Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments MarketWatch
07:30AM  Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimers Disease and Parkinsons Disease from Pfizer Inc. GlobeNewswire
Jan-10-20 08:05PM  Biogen Defends Its Blockbuster Against Mylans Patent Challenge
07:00AM  Biogen signs neuro disease drug deal with Cambridge startup American City Business Journals
Jan-09-20 09:20AM  4 Things to Pay Attention to at the J.P. Morgan Health-Care Conference Next Week
08:00AM  Red-Hot Biotech Stocks Brace For Key Meeting Here's What To Expect Investor's Business Daily
Jan-08-20 07:30AM  Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy PR Newswire
Jan-07-20 11:00AM  Top Health Care Stocks for January 2020 Investopedia
08:00AM  Is Biogen Stock A Buy On Renewed Hope In Alzheimer's Disease? Investor's Business Daily
Jan-06-20 09:38AM  Biogen Faces a Looming Patent Decision. Heres How Much Its Stock Could Drop If It Loses.
Jan-02-20 10:08AM  Drug-Price Increases Show Business as Usual Despite Public Pressure
08:41AM  Bristol-Myers, Gilead, Biogen, Other Drugmakers Increased U.S. List Prices on Jan. 1: Report
Jan-01-20 11:47AM  More drugmakers hike U.S. prices as new year begins Reuters
Dec-30-19 11:02AM  Why Biogen Inc. (NASDAQ:BIIB) Looks Like A Quality Company Simply Wall St.
Dec-26-19 11:14AM  2020 Vision: In Biogen, industry could see 1st new Alzheimer's drug in years American City Business Journals
Dec-25-19 08:20PM  How Did Biogen Inc. (BIIB) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-24-19 07:00AM  Heres to Your Health: A Decade of Drug Breakthroughs Bloomberg
Dec-23-19 02:47PM  Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
Dec-21-19 11:24AM  Barron's Picks And Pans: Alibaba, Biogen, China Mobile, Peter Lynch Picks And More Benzinga
08:00AM  Biogen Announced a Big Stock Buyback. It May Not Be a Great Use of Cash.
Dec-20-19 12:00PM  Stock Upgrades: Biogen Shows Rising Relative Strength Investor's Business Daily
08:03AM  Dow Jones Futures: Nike, Biogen, Winnebago Lead 5 Stocks Near Buy Points Moving On News Investor's Business Daily
05:00AM  Biogen- What's Next in Alzheimer's Research MoneyShow
04:37AM  Biogen Climbs on $5 billion Share Buyback Program
Dec-19-19 05:07PM  Biogen Stock Is Jumping After Announcing a $5 Billion Share Buyback
10:13AM  The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
10:01AM  AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU Zacks
08:00AM  Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration GlobeNewswire
07:05AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-18-19 05:52PM  3 'Magic Formula' Companies Investing in Growth
05:30PM  5 Attractive Christmas Deals: Stocks With High Value and Quality
02:27PM  Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-16-19 08:05AM  Biogen's Gosuranemab Fails in Phase II Brain Disorder Study Zacks
Dec-13-19 10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick.
07:40AM  Biogen to discontinue development of treatment for rare brain disorder after trial misses goals MarketWatch
07:30AM  Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy GlobeNewswire
Dec-09-19 11:10AM  Investors Are Moving Back Into Resurgent Biotech ETFs ETF Trends
09:42AM  J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH Zacks
Dec-08-19 12:29PM  Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More Benzinga
Dec-06-19 04:31PM  Biogen Edges Near Breakout But Will Its Alzheimer's Drug Pass Muster? Investor's Business Daily
03:08PM  Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch
11:52AM  Biogen CEO on Controversial Alzheimers Drug: There Is Hope Meredith Videos
11:19AM  Risks of Biogen Alzheimers Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James
10:58AM  Cassava stock is up on Alzheimer's data MarketWatch
10:22AM  Money Is Moving Back Into Surging Biotech Funds
09:55AM  Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation Benzinga
09:30AM  Biogen Up on New Data on Alzheimer's Candidate Aducanumab Zacks
Dec-05-19 08:50PM  After Biogen's big Alzheimer's drug data reveal, observers remain divided American City Business Journals
07:35PM  Eisai, Partner Biogen Gain as Alzheimers Drug Studies Revived Bloomberg
04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions
04:07PM  Biogen Stock Pops: Here's What Happened In Its Alzheimer's Update Investor's Business Daily
04:06PM  Biogen Stock Is Rising After a Presentation at an Alzheimers Conference
02:50PM  Wild Biotech Day Sparks $7.6 Billion Shuffle for Neurology Trio Bloomberg
02:19PM  Biogen stock climbs as investors shrug off analyst skepticism about Alzheimers drug MarketWatch
02:01PM  Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response Benzinga
01:44PM  Biogen Has More Hope Than Data for Alzheimers Drug Bloomberg
12:56PM  The Dow Goes Negative Despite a Glimmer of Hope on Trade
12:22PM  Biogen shares rise on Alzheimer's candidate data MarketWatch
10:08AM  Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data
09:51AM  UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy Reuters
08:51AM  Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up Zacks
08:15AM  Biogen Shares Up After Alzheimer Drug Tests Show No New Concerns
06:00AM  Biogen to make case to skeptics for its controversial Alzheimer's drug Reuters
02:00AM  OPEC, Huawei, PG&E, Biogen, and a 2020 Recession? - 5 Things You Must Know
Dec-04-19 10:25AM  Biogen's Lupus Candidate Meets Endpoint in Phase II Study Zacks
10:13AM  Anavex shares rise in advance of Alzheimer's meeting MarketWatch
10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 11:22AM  Cramer Weighs In On Biogen, Caterpillar And More Benzinga
09:29AM  Biogen's Shares Down on Rating Downgrade by Baird Analyst Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
07:30AM  Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) GlobeNewswire
Dec-02-19 04:13PM  Biogen Stock Is Facing A Crucial Test Here's What You Need To Know Investor's Business Daily
01:56PM  Biogen's shares drop on critical view of Alzheimer's data MarketWatch
01:55PM  Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade Benzinga
10:25AM  Biogens Alzheimers Drug Wont Get Approved, Analyst Says
09:48AM  Biogen Downgraded by Baird Analyst Over Move to Salvage Alzheimers Drug Bloomberg
06:24AM  Have Insiders Been Buying Biogen Inc. (NASDAQ:BIIB) Shares? Simply Wall St.
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-28-19 10:24PM  Hedge Funds Warming Up To Biogen Inc. (BIIB) Again Insider Monkey
07:00AM  The 3 Worst-Performing Health Care Stocks of 2019 So Far
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
08:52AM  ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-25-19 04:59PM  Roche's NDA for SMA Drug Risdiplam Gets Priority Review Zacks
02:45PM  Biogen Sees Its Composite Rating Rise To 97 Investor's Business Daily
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM